ArticleMolecular biotechnology2026
TFAP2A-mediated Transcriptional Activation of ELMO1 Inhibits Ferroptosis and Promotes Esophageal Squamous Cell Carcinoma Progression.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The role of engulfment and cell motility protein 1 (ELMO1) in esophageal squamous cell carcinoma (ESCC) is still unknown, even though it is critical for cellular behaviors. Our bioinformatics analyses have predicted transcription factor AP-2 alpha (TFAP2A) as a potential upstream regulator of ELMO1, suggesting its involvement in ESCC progression. ELMO1 expression in ESCC cells was analyzed. Lentivirus-mediated gene silencing was conducted, while cell counting kit-8, wound healing, and transwell assays evaluated the effects of ELMO1 on ESCC cell activities. The transcriptional regulatory effect of TFAP2A on ELMO1 was verified using dual-luciferase reporter assays and ChIP-qPCR. Additionally, ferroptosis-related indicators were detected to explore the potential role of TFAP2A/ELMO1 in ESCC. A nude mouse xenograft model was established to analyze tumor growth in vivo. ELMO1 was upregulated in KYSE150 cells. Silencing of ELMO1 suppressed ESCC cell migration and invasion, while sensitizing cells to ferroptosis. TFAP2A transcriptionally activated ELMO1 by binding to its promoter, thereby enhancing ESCC cell invasive potential. In vivo, TFAP2A knockdown activated ferroptosis and inhibited tumor growth, whereas ELMO1 overexpression promoted tumor progression. TFAP2A facilitates ESCC cell proliferation, migration, and invasion by promoting ELMO1 transcription and inhibiting ferroptosis. Both TFAP2A and ELMO1 act as oncogenic drivers in ESCC and may represent potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.